$GRTSQ
Gritstone bio, Inc.

2020 Q3 Form 10-Q Financial Statement

#000156459020036449 Filed on August 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2020 Q2 2019 Q2
Revenue $939.0K $488.0K $1.150M
YoY Change -4.57% -57.57%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.030M $5.260M $4.840M
YoY Change 9.83% 8.68% 72.24%
% of Gross Profit
Research & Development $22.05M $21.29M $18.53M
YoY Change -11.4% 14.9% 46.02%
% of Gross Profit
Depreciation & Amortization $1.670M $1.650M $1.090M
YoY Change 42.74% 51.38% 12.37%
% of Gross Profit
Operating Expenses $27.08M $26.55M $23.36M
YoY Change -8.1% 13.61% 50.71%
Operating Profit -$26.14M -$26.06M -$22.21M
YoY Change -8.22% 17.3% 43.28%
Interest Expense $69.00K $189.0K $1.042M
YoY Change -92.63% -81.86% 3261.29%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$26.07M -$25.87M -$21.17M
YoY Change -5.37% 22.2% 36.85%
Income Tax
% Of Pretax Income
Net Earnings -$26.07M -$25.87M -$21.17M
YoY Change -5.35% 22.18% 36.83%
Net Earnings / Revenue -2776.68% -5300.82% -1841.04%
Basic Earnings Per Share
Diluted Earnings Per Share -$690.6K -$694.3K -$630.4K
COMMON SHARES
Basic Shares Outstanding 37.75M 35.72M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $70.50M $91.90M $181.2M
YoY Change -52.84% -49.28% 180.93%
Cash & Equivalents $57.65M $62.63M $107.7M
Short-Term Investments $12.90M $29.30M $73.50M
Other Short-Term Assets $403.0K $290.0K $389.0K
YoY Change -50.06% -25.45% -83.79%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $73.70M $94.50M $184.7M
YoY Change -52.39% -48.84% 176.08%
LONG-TERM ASSETS
Property, Plant & Equipment $23.31M $24.58M $18.97M
YoY Change -52.63% 29.61% -31.03%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $500.0K
YoY Change
Other Assets $2.700M $2.700M $100.0K
YoY Change 0.0% 2600.0% -93.33%
Total Long-Term Assets $48.80M $51.17M $43.48M
YoY Change -9.46% 17.68% 49.43%
TOTAL ASSETS
Total Short-Term Assets $73.70M $94.50M $184.7M
Total Long-Term Assets $48.80M $51.17M $43.48M
Total Assets $122.5M $145.7M $228.2M
YoY Change -41.3% -36.16% 137.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.300M $4.301M $5.253M
YoY Change -50.75% -18.12% 94.56%
Accrued Expenses $13.20M $138.0K $1.803M
YoY Change 22.22% -92.35% -27.88%
Deferred Revenue $5.778M $5.498M
YoY Change 5.09%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $22.00M $19.18M $18.07M
YoY Change -3.9% 6.14% 247.4%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $28.50M $375.0K $27.70M
YoY Change -3.06% -98.65% 1631.25%
Total Long-Term Liabilities $28.50M $375.0K $27.70M
YoY Change -3.06% -98.65% 128.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.00M $19.18M $18.07M
Total Long-Term Liabilities $28.50M $375.0K $27.70M
Total Liabilities $50.50M $49.44M $45.80M
YoY Change -3.44% 7.94% 164.75%
SHAREHOLDERS EQUITY
Retained Earnings -$299.1M -$273.1M -$165.7M
YoY Change 64.78%
Common Stock $17.00K $17.00K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $71.98M $96.23M $182.4M
YoY Change
Total Liabilities & Shareholders Equity $122.5M $145.7M $228.2M
YoY Change -41.3% -36.16% 137.69%

Cashflow Statement

Concept 2020 Q3 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$26.07M -$25.87M -$21.17M
YoY Change -5.35% 22.18% 36.83%
Depreciation, Depletion And Amortization $1.670M $1.650M $1.090M
YoY Change 42.74% 51.38% 12.37%
Cash From Operating Activities -$20.18M -$20.73M -$18.41M
YoY Change -19.34% 12.6% 53.29%
INVESTING ACTIVITIES
Capital Expenditures -$610.0K -$1.020M -$2.250M
YoY Change -89.39% -54.67% 92.31%
Acquisitions
YoY Change
Other Investing Activities $16.35M $24.84M $24.03M
YoY Change -58.85% 3.37% 88.47%
Cash From Investing Activities $15.73M $23.83M $21.78M
YoY Change -53.71% 9.41% 88.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $69.70M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 40.00K 4.670M 69.79M
YoY Change -84.0% -93.31% 748.0%
NET CHANGE
Cash From Operating Activities -20.18M -20.73M -18.41M
Cash From Investing Activities 15.73M 23.83M 21.78M
Cash From Financing Activities 40.00K 4.670M 69.79M
Net Change In Cash -4.410M 7.770M 73.16M
YoY Change -147.88% -89.38% 837.95%
FREE CASH FLOW
Cash From Operating Activities -$20.18M -$20.73M -$18.41M
Capital Expenditures -$610.0K -$1.020M -$2.250M
Free Cash Flow -$19.57M -$19.71M -$16.16M
YoY Change 1.56% 21.97% 49.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q2 grts Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
2679000
CY2020Q2 us-gaap Assets
Assets
145666000
CY2020Q2 grts Use Of Business Incentive Tax Credits Period Cap
UseOfBusinessIncentiveTaxCreditsPeriodCap
P3Y
CY2020Q2 grts Lapse Of Repurchase Rights Related To Common Stock Issued Pursuant To Early Exercises
LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises
3000
CY2020Q2 grts Use Of Net Operating Losses Suspension Period For Medium And Large Business
UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness
P3Y
us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201602Member
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y3M18D
CY2019Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y3M18D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y5M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y8M15D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y6M14D
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23909000
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
145666000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4093000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
527000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
70000
dei Entity File Number
EntityFileNumber
001-38663
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Trading Symbol
TradingSymbol
GRTS
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Central Index Key
EntityCentralIndexKey
0001656634
dei Entity Registrant Name
EntityRegistrantName
Gritstone Oncology, Inc.
dei Entity Address City Or Town
EntityAddressCityOrTown
Emeryville
dei Local Phone Number
LocalPhoneNumber
871-6100
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94608
dei City Area Code
CityAreaCode
510
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Address Address Line1
EntityAddressAddressLine1
5959 Horton Street
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20985000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
131273000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57408000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
94497000
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
50000
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2584000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
96228000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
134344000
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22258000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
355291000
CY2020Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
7630000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
24000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62631000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-273062000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-220988000
CY2020Q2 us-gaap Liabilities
Liabilities
49438000
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
17000
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
369223000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3497000
CY2019Q4 grts Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
2778000
CY2019Q4 us-gaap Assets
Assets
184389000
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4301000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4598000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
138000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1041000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
17000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24581000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2505000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4956000
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4859534
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19500000
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
CY2020Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
5778000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
19175000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
70368000
CY2020Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
29282000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4621000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
26911000
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3765000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
9560000
CY2019Q4 us-gaap Liabilities
Liabilities
50045000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23427000
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q2 grts Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
953000
CY2019Q4 grts Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1779000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4240000
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
375000
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37749059
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
184389000
grts Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
-825000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
57000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1957000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-25868000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
96228000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
132222000
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9000
CY2019Q2 grts Lapse Of Repurchase Rights Related To Common Stock Issued Pursuant To Early Exercises
LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises
17000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
276000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1317000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-21172000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
182378000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
134344000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9670000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
527000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
26000
grts Lapse Of Repurchase Rights Related To Common Stock Issued Pursuant To Early Exercises
LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises
11000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
148000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3576000
us-gaap Net Income Loss
NetIncomeLoss
-52074000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
96228000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
149122000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
161000
grts Lapse Of Repurchase Rights Related To Common Stock Issued Pursuant To Early Exercises
LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises
34000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
362000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2324000
us-gaap Net Income Loss
NetIncomeLoss
-39181000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
182378000
us-gaap Net Income Loss
NetIncomeLoss
-52074000
us-gaap Net Income Loss
NetIncomeLoss
-39181000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3277000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2130000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
113000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
970000
us-gaap Share Based Compensation
ShareBasedCompensation
3576000
us-gaap Share Based Compensation
ShareBasedCompensation
2324000
us-gaap Operating Lease Cost
OperatingLeaseCost
3712000
us-gaap Operating Lease Cost
OperatingLeaseCost
2837000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-897000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-268000
grts Increase Decrease In Deposit And Other Assets Noncurrent
IncreaseDecreaseInDepositAndOtherAssetsNoncurrent
-99000
grts Increase Decrease In Deposit And Other Assets Noncurrent
IncreaseDecreaseInDepositAndOtherAssetsNoncurrent
272000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
599000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-867000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-835000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1329000
grts Increase Decrease In Accrued And Other Liabilities Non Current
IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent
256000
grts Increase Decrease In Accrued And Other Liabilities Non Current
IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent
1312000
grts Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-1169000
grts Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-1293000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1108000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2497000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43708000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37538000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
8809000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
16012000
grts Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
44632000
grts Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
44050000
grts Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
5401000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2625000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4831000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
38599000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
23207000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10435000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
70432000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
103000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
556000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10332000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
69876000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5223000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
55545000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53175000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
63623000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
108720000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
315000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2775000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q2 grts Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
91900000
CY2019Q4 grts Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
127800000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-273100000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-221000000.0
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-25900000
us-gaap Net Income Loss
NetIncomeLoss
-52100000
us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
0
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-21200000
us-gaap Net Income Loss
NetIncomeLoss
-39200000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43700000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37500000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses in the condensed consolidated financial statements and accompanying notes during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to preclinical and clinical study trial accruals, fair value of assets and liabilities, the fair value of right-of-use assets (“ROU assets”) and lease liabilities, revenue recognition, and the fair value of stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-right:1.07%;text-indent:6.92%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents, and marketable securities. Cash, cash equivalents and marketable securities are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. The Company maintains cash equivalents and marketable securities with various high-credit-quality and capitalized financial institutions. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.92%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents, and marketable securities and issuers of marketable securities to the extent recorded on the balance sheets. Through June 30, 2020, the Company has no off-balance sheet concentrations of credit risk<span style="color:#000000;">.</span></p>
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62631000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57408000
CY2020Q2 us-gaap Restricted Cash
RestrictedCash
992000
CY2019Q4 us-gaap Restricted Cash
RestrictedCash
992000
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
63623000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
58400000
CY2020Q2 grts Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
79603000
CY2020Q2 grts Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
50000
CY2020Q2 grts Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
79653000
CY2019Q4 grts Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
116726000
CY2019Q4 grts Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
30000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000
CY2019Q4 grts Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
116750000
grts Marketable Securities Realized Gain Loss Description
MarketableSecuritiesRealizedGainLossDescription
no material realized gains or losses
CY2020Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
4
CY2020Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2020Q2 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q2 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
38167000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
37221000
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13586000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10310000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24581000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
26911000
CY2020Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1700000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3300000
CY2019Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1100000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2100000
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1862000
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1493000
us-gaap Operating Lease Cost
OperatingLeaseCost
3712000
us-gaap Operating Lease Cost
OperatingLeaseCost
2837000
CY2019Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
65000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
8000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
122000
CY2020Q2 us-gaap Lease Cost
LeaseCost
1862000
CY2019Q2 us-gaap Lease Cost
LeaseCost
1558000
us-gaap Lease Cost
LeaseCost
3720000
us-gaap Lease Cost
LeaseCost
2959000
us-gaap Operating Lease Payments
OperatingLeasePayments
2105000
us-gaap Operating Lease Payments
OperatingLeasePayments
1293000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3084000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
342000
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.090
CY2019Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.090
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3238000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.61
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7841000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5837000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3459000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
3449000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
12530000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
36354000
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9204000
CY2020Q2 grts Operating Lease Tenant Improvement Allowance
OperatingLeaseTenantImprovementAllowance
652000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
26498000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4240000
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22258000
CY2020Q2 us-gaap Prepaid Insurance
PrepaidInsurance
424000
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1252000
CY2020Q2 grts Interest And Other Receivables Current
InterestAndOtherReceivablesCurrent
293000
CY2019Q4 grts Interest And Other Receivables Current
InterestAndOtherReceivablesCurrent
482000
CY2020Q2 grts Prepaid Expense For Research And Development
PrepaidExpenseForResearchAndDevelopment
1577000
CY2019Q4 grts Prepaid Expense For Research And Development
PrepaidExpenseForResearchAndDevelopment
1473000
CY2020Q2 us-gaap Other Assets Current
OtherAssetsCurrent
290000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
290000
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2584000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3497000
CY2020Q2 us-gaap Security Deposit
SecurityDeposit
1218000
CY2019Q4 us-gaap Security Deposit
SecurityDeposit
1201000
CY2020Q2 grts Prepaid Expense For Research And Development Non Current
PrepaidExpenseForResearchAndDevelopmentNonCurrent
469000
CY2019Q4 grts Prepaid Expense For Research And Development Non Current
PrepaidExpenseForResearchAndDevelopmentNonCurrent
585000
CY2020Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
992000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
992000
CY2020Q2 grts Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
2679000
CY2019Q4 grts Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
2778000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1758300
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
14516000
grts Contract With Customer Liability Addition
ContractWithCustomerLiabilityAddition
0
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-1108000
CY2020Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
13408000
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Holders of the Company’s common stock are entitled to one vote per share.
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37713218
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37713218
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36332956
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36332956
CY2019Q4 grts Maximum Securities Covered Under Registration Agreement
MaximumSecuritiesCoveredUnderRegistrationAgreement
250000000.0
CY2019Q4 grts Percentage Of Proceeds Payable As Compensation To Underwriter
PercentageOfProceedsPayableAsCompensationToUnderwriter
0.030
CY2019Q4 grts Maximum Offering Expenses Agreed To Be Reimbursed
MaximumOfferingExpensesAgreedToBeReimbursed
50000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2851883
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3165961
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.83
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8875000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
1454553
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1758300
grts Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
92191
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.61
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
148555
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
148555
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.78
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2696691
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4683515
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.12
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5420000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1557795
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
6.31
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
4091000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4250866
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.00
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
5342000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
600000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2600000
CY2020Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
15800000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M2D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3300000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1957000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1317000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3576000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2324000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-25868000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-21172000
us-gaap Net Income Loss
NetIncomeLoss
-52074000
us-gaap Net Income Loss
NetIncomeLoss
-39181000
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37256247
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33582844
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37027405
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31273696
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.63
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.41
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.25

Files In Submission

Name View Source Status
0001564590-20-036449-index-headers.html Edgar Link pending
0001564590-20-036449-index.html Edgar Link pending
0001564590-20-036449.txt Edgar Link pending
0001564590-20-036449-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
grts-10q_20200630.htm Edgar Link pending
grts-10q_20200630_htm.xml Edgar Link completed
grts-20200630.xsd Edgar Link pending
grts-20200630_cal.xml Edgar Link unprocessable
grts-20200630_def.xml Edgar Link unprocessable
grts-20200630_lab.xml Edgar Link unprocessable
grts-20200630_pre.xml Edgar Link unprocessable
grts-ex101_78.htm Edgar Link pending
grts-ex311_9.htm Edgar Link pending
grts-ex312_6.htm Edgar Link pending
grts-ex321_7.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending